TWI800691B - 抑制α4β7整合素的化合物 - Google Patents
抑制α4β7整合素的化合物 Download PDFInfo
- Publication number
- TWI800691B TWI800691B TW108139359A TW108139359A TWI800691B TW I800691 B TWI800691 B TW I800691B TW 108139359 A TW108139359 A TW 108139359A TW 108139359 A TW108139359 A TW 108139359A TW I800691 B TWI800691 B TW I800691B
- Authority
- TW
- Taiwan
- Prior art keywords
- integrin
- inhibition
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
- C07D321/02—Seven-membered rings
- C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862752859P | 2018-10-30 | 2018-10-30 | |
US62/752,859 | 2018-10-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202033493A TW202033493A (zh) | 2020-09-16 |
TWI800691B true TWI800691B (zh) | 2023-05-01 |
Family
ID=68582497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW108139359A TWI800691B (zh) | 2018-10-30 | 2019-10-30 | 抑制α4β7整合素的化合物 |
Country Status (9)
Country | Link |
---|---|
US (2) | US11224600B2 (zh) |
EP (1) | EP3873897A1 (zh) |
JP (2) | JP7189368B2 (zh) |
KR (1) | KR102652797B1 (zh) |
CN (1) | CN112996786A (zh) |
AU (1) | AU2019373242B2 (zh) |
CA (1) | CA3115820A1 (zh) |
TW (1) | TWI800691B (zh) |
WO (1) | WO2020092383A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
CA3115820A1 (en) * | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
BR112021007213A2 (pt) | 2018-10-30 | 2021-08-10 | Gilead Sciences, Inc. | derivados de quinolina como inibidores de integrina alfa4beta7 |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
UY38926A (es) | 2019-10-16 | 2021-05-31 | Morphic Therapeutic Inc | INHIBICIÓN DE INTEGRINA alfa4beta7 HUMANA |
AR128112A1 (es) * | 2021-12-28 | 2024-03-27 | Alchemedicine Inc | Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999036393A1 (en) * | 1998-01-20 | 1999-07-22 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Family Cites Families (231)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0673247A4 (en) | 1992-12-01 | 1996-05-01 | Merck & Co Inc | FIBRINOGEN RECEPTOR ANTAGONISTS. |
JPH10502349A (ja) | 1994-06-29 | 1998-03-03 | テキサス・バイオテクノロジー・コーポレイシヨン | インテグリンα▲下4▼β▲下1▼のVCAM−1またはフィブロネクチンへの結合を阻害する方法 |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
KR19990036271A (ko) | 1995-08-08 | 1999-05-25 | 토마스 네프 | 콜라겐 과다생산과 연관된 질환의 치료에 이용되는 c-프로테나제 저해물질 |
SG158733A1 (en) | 1996-07-25 | 2010-02-26 | Biogen Idec Inc | Cell adhesion inhibitors |
WO1998042656A1 (en) | 1997-03-21 | 1998-10-01 | Cytel Corporation | Novel compounds |
WO1998053814A1 (en) | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
JP2002501537A (ja) | 1997-05-29 | 2002-01-15 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としてのスルホンアミド類 |
AU726585B2 (en) | 1997-05-29 | 2000-11-09 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6482849B1 (en) | 1997-06-23 | 2002-11-19 | Tanabe Seiyaku Co., Ltd. | Inhibitors of α4β1 mediated cell adhesion |
WO1999006431A1 (en) | 1997-07-31 | 1999-02-11 | Elan Pharmaceuticals, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
BR9811573A (pt) | 1997-07-31 | 2000-09-19 | Elan Pharm Inc | Compostos de benzila que inibem a adesão de leucócitos mediada por vla-4 |
JP2001512139A (ja) | 1997-07-31 | 2001-08-21 | エラン・ファーマシューティカルズ・インコーポレーテッド | Vla−4が介在する白血球接着を阻害するスルホニル化ジペプチド化合物 |
AR014903A1 (es) | 1997-07-31 | 2001-04-11 | Athena Neurosciences Inc | Compuestos del tipo 4-amino-fenilalanina inhibidores de la adhesion de leucocitos intermediada por vla-4, compuesto que son droga de dichos compuestos,composiciones farmaceuticas, metodo para adherir vla-4 en una muestra biologica, metodo para tratar una condicion inflamatoria |
WO1999013898A1 (en) | 1997-08-15 | 1999-03-25 | Stefan Niewiarowski | EC-3, AN INHIBITOR OF α4β1 AND α4β7 INTEGRINS |
ATE260243T1 (de) | 1997-08-22 | 2004-03-15 | Hoffmann La Roche | N-aroylphenylalaninderivate |
DE69824183T2 (de) | 1997-08-22 | 2005-04-21 | Hoffmann La Roche | N-alkanoylphenylalaninderivate |
US6511961B1 (en) | 1997-11-13 | 2003-01-28 | Toray Industries, Inc. | Cyclic peptides and medicinal use thereof |
ATE267168T1 (de) | 1997-11-24 | 2004-06-15 | Merck & Co Inc | Beta-alanin-derivate als zell-adhäsions- inhibitoren |
US6271252B1 (en) | 1997-11-24 | 2001-08-07 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
EP1044001B1 (en) | 1997-12-17 | 2005-07-06 | Merck & Co., Inc. | Integrin receptor antagonists |
SK15592000A3 (sk) | 1998-04-16 | 2001-12-03 | Texas Biotechnology Corporation | N,n-disubstituované amidy, ktoré inhibujú viazanie integrínov na ich receptory |
IL139967A (en) | 1998-05-28 | 2005-11-20 | Biogen Idec Inc | Beta-alanine derivatives and pharmaceutical compositions containing the same |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
AU8059598A (en) | 1998-06-11 | 1999-12-30 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
TW591026B (en) | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
WO2000002903A1 (en) | 1998-07-10 | 2000-01-20 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
AU5052199A (en) | 1998-07-23 | 2000-02-14 | Astrazeneca Ab | Chemical compounds |
GB9818641D0 (en) | 1998-08-26 | 1998-10-21 | Rh Ne Poulenc Rorer Limited | Chemical compounds |
KR20010085630A (ko) | 1998-08-26 | 2001-09-07 | 앤드류 앵뉴 | 세포 접착 억제를 조절하는 아자-비사이클 |
BR9916211A (pt) | 1998-12-14 | 2001-09-11 | American Home Prod | Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesão de leucócito mediada por vla-4 |
GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
WO2000043354A2 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2000043372A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Acyl derivatives which treat vla-4 related disorders |
CA2359112A1 (en) | 1999-01-22 | 2000-07-27 | Elan Pharmaceuticals, Inc. | Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
AU2623800A (en) | 1999-01-26 | 2000-08-07 | American Home Products Corporation | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 |
WO2000048994A1 (en) | 1999-02-18 | 2000-08-24 | F. Hoffmann-La Roche Ag | Thioamide derivatives |
ATE264298T1 (de) | 1999-03-01 | 2004-04-15 | Elan Pharm Inc | Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten |
US6265572B1 (en) | 1999-04-20 | 2001-07-24 | Hoffmann-La Roche Inc. | Pyrrolidincarbonylamino cyclic disulfide anti-inflammatory agents |
GB9909409D0 (en) | 1999-04-24 | 1999-06-23 | Zeneca Ltd | Chemical compounds |
DK1176956T3 (da) | 1999-05-07 | 2008-05-26 | Encysive Pharmaceuticals Inc | Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer |
EP1189612A4 (en) | 1999-06-30 | 2005-02-16 | Daiichi Seiyaku Co | VLA-4 INHIBITORY COMPOUNDS |
JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
AU6314200A (en) | 1999-07-26 | 2001-02-13 | Toray Industries, Inc. | Carboxylic acid derivatives and adhesion molecule inhibitors containing the sameas the active ingredient |
BR0013248A (pt) | 1999-08-13 | 2002-07-23 | Biogen Inc | Inibidores da adesão celular |
WO2001012183A1 (en) | 1999-08-16 | 2001-02-22 | Merck & Co., Inc. | Heterocycle amides as cell adhesion inhibitors |
WO2001014328A2 (en) | 1999-08-20 | 2001-03-01 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
ES2288871T3 (es) | 1999-09-24 | 2008-02-01 | Genentech, Inc. | Derivados de tirosina. |
WO2001032610A1 (fr) | 1999-10-29 | 2001-05-10 | Kaken Pharmaceutical Co., Ltd. | Derive d'uree, son procede de production, et produit pharmaceutique contenant ce derive d'uree |
WO2001036376A1 (fr) | 1999-11-18 | 2001-05-25 | Ajinomoto Co., Inc. | Nouveaux dérivés de la phénylalanine |
CN1196682C (zh) | 1999-12-06 | 2005-04-13 | 霍夫曼-拉罗奇有限公司 | 4-吡啶基-n-酰基-l-苯丙氨酸 |
PT1237878E (pt) | 1999-12-06 | 2007-06-18 | Hoffmann La Roche | 4-pirimidinil-n-acil-fenilalaninas |
EP1242118B1 (en) | 1999-12-16 | 2009-11-11 | Biogen Idec MA Inc. | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
DE19962936A1 (de) | 1999-12-24 | 2001-06-28 | Bayer Ag | Neue beta-Aminosäureverbindungen als Integrinantagonisten |
WO2001047868A1 (fr) | 1999-12-28 | 2001-07-05 | Ajinomoto Co., Inc. | Nouveaux derives de phenylalanine |
GB0001348D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
GB0001346D0 (en) | 2000-01-21 | 2000-03-08 | Astrazeneca Uk Ltd | Chemical compounds |
WO2001055121A1 (fr) | 2000-01-28 | 2001-08-02 | Kaken Pharmaceutical Co., Ltd. | Dérivés d'azépine |
CN100356979C (zh) | 2000-02-03 | 2007-12-26 | 卫材R&D管理有限公司 | 整联蛋白表达抑制剂 |
AU2001234741A1 (en) | 2000-02-04 | 2001-08-14 | Biogen, Inc. | Integrin antagonists |
AU2001262089A1 (en) | 2000-03-14 | 2001-09-24 | Novartis Ag | Alpha4beta1 and alpha4beta7 integrin inhibitors |
AU2001242743A1 (en) | 2000-03-23 | 2001-10-03 | Ajinomoto Co. Inc. | Novel phenylalanine derivative |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
US6689781B2 (en) | 2000-07-21 | 2004-02-10 | Elan Pharmaceuticals, Inc. | Phenylalanine derivatives as alpha 4 integrin inhibitors |
PE20020384A1 (es) | 2000-07-21 | 2002-05-28 | Schering Corp | PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C |
US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
JP5046466B2 (ja) | 2000-08-11 | 2012-10-10 | 科研製薬株式会社 | 2,3−ジフェニルプロピオン酸誘導体またはその塩、それを用いた医薬および細胞接着阻害剤ならびにその使用方法 |
CA2419580A1 (en) | 2000-08-18 | 2002-02-28 | Genentech, Inc. | Integrin receptor inhibitors |
AU7874001A (en) | 2000-08-18 | 2002-03-04 | Ajinomoto Kk | Novel phenylalanine derivatives |
MY129000A (en) | 2000-08-31 | 2007-03-30 | Tanabe Seiyaku Co | INHIBITORS OF a4 MEDIATED CELL ADHESION |
KR20030036724A (ko) | 2000-09-14 | 2003-05-09 | 도레이 가부시끼가이샤 | 우레아 유도체 및 그것을 유효성분으로 하는 접착분자저해제 |
WO2002024697A1 (fr) | 2000-09-25 | 2002-03-28 | Toray Industries, Inc. | Composes spiro et inhibiteurs de molecules d'adhesion contenant ces composes comme ingredient actif |
ATE345127T1 (de) | 2000-09-29 | 2006-12-15 | Ajinomoto Kk | Neue phenylalanin-derivate |
IL156064A0 (en) | 2000-12-28 | 2003-12-23 | Daiichi Seiyaku Co | Vla-4 inhibitors |
ES2200617B1 (es) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | Derivados de urea como antagonistas de integrinas alfa 4. |
CN101025419A (zh) | 2001-02-21 | 2007-08-29 | 卫材R&D管理有限公司 | 测定通过抑制整联蛋白表达所介导的血管生成抑制剂的作用的方法 |
PL364142A1 (en) | 2001-02-22 | 2004-12-13 | Celltech R & D Limited | Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
DE60140013D1 (de) | 2001-06-20 | 2009-11-05 | Asahi Chemical Ind | Thermoplastharzzusammensetzung |
JP2005022976A (ja) | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | カルボン酸誘導体 |
JP4164871B2 (ja) | 2001-07-26 | 2008-10-15 | 味の素株式会社 | 新規フェニルプロピオン酸誘導体 |
WO2003011815A1 (en) | 2001-07-26 | 2003-02-13 | Celltech R & D Limited | Bicyclic heteroaromatic alanines |
JP2003048889A (ja) | 2001-08-01 | 2003-02-21 | Ajinomoto Co Inc | 新規核酸系化合物 |
EP1424558A4 (en) | 2001-08-17 | 2004-12-15 | Eisai Co Ltd | REAGENT FOR TESTING LAMININE-5-ANTIGENS IN A BIOLOGICAL SAMPLE AND TEST PROCEDURE |
EP1426360A4 (en) | 2001-09-12 | 2006-04-12 | Kaken Pharma Co Ltd | 2-PHENYL-3-HETEROARYLPROPIONIC ACID DERIVATIVE OR SALT THEREOF AND MEDICAMENTS CONTAINING THE SAME |
GB0127423D0 (en) | 2001-11-15 | 2002-01-09 | Glaxo Group Ltd | Process |
JP4452899B2 (ja) | 2001-12-13 | 2010-04-21 | 味の素株式会社 | 新規フェニルアラニン誘導体 |
WO2003070709A1 (fr) | 2002-02-20 | 2003-08-28 | Ajinomoto Co.,Inc. | Nouveau derive de phenylalanine |
JP4233353B2 (ja) | 2002-02-27 | 2009-03-04 | 田辺三菱製薬株式会社 | 医薬組成物 |
MY140707A (en) | 2002-02-28 | 2010-01-15 | Mitsubishi Tanabe Pharma Corp | Process for preparing a phenylalanine derivative and intermediates thereof |
JP2003277340A (ja) | 2002-03-22 | 2003-10-02 | Toray Ind Inc | 接着分子阻害剤及び新規アミノ酸誘導体 |
JPWO2003080611A1 (ja) | 2002-03-22 | 2005-07-21 | 東レ株式会社 | スピロ誘導体及びそれを有効成分とする接着分子阻害剤 |
WO2003089410A1 (fr) | 2002-04-19 | 2003-10-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de phenylalanine |
RU2315041C2 (ru) | 2002-04-30 | 2008-01-20 | ЮСиБи, С.А. | Производные 2,6-хинолинила и 2,6-нафтила, фармацевтические композиции на их основе, их применение в качестве ингибиторов vla-4 и промежуточные соединения |
TW200307671A (en) | 2002-05-24 | 2003-12-16 | Elan Pharm Inc | Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins |
TWI281470B (en) | 2002-05-24 | 2007-05-21 | Elan Pharm Inc | Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins |
GB0216571D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
GB0216568D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
GB0216574D0 (en) | 2002-07-17 | 2002-08-28 | Celltech R&D Ltd | Chemical compounds |
JP2005535710A (ja) | 2002-08-09 | 2005-11-24 | トランス テック ファーマ,インコーポレイテッド | アリールおよびヘテロアリール化合物ならびに凝固を調節する方法 |
GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
CA2851462A1 (en) | 2003-01-08 | 2004-07-29 | University Of Washington | Antibacterial agents |
CA2514117A1 (en) | 2003-01-24 | 2004-08-12 | Elan Pharmaceuticals, Inc. | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents |
CN101386600B (zh) | 2003-02-20 | 2011-07-06 | 味之素株式会社 | 具有喹唑二酮骨架的苯丙氨酸衍生物的制造方法及制造中间体 |
JP2004277338A (ja) | 2003-03-14 | 2004-10-07 | Nippon Soda Co Ltd | N−アシルアミノ酸類の製造方法 |
ES2219177B1 (es) | 2003-05-05 | 2006-02-16 | Almirall Prodesfarma, S.A. | Derivados de n-(2-feniletil) sulfamida como antagonistas de la integrina alfa4. |
JP2006528988A (ja) | 2003-05-20 | 2006-12-28 | ジェネンテック・インコーポレーテッド | アルファ−4インテグリンのチオカルバメート阻害剤 |
WO2005000244A2 (en) | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
EP1650205B1 (en) | 2003-07-24 | 2012-04-25 | Daiichi Sankyo Company, Limited | Cyclohexanecarboxylic acid compound |
WO2005014534A1 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
JPWO2005040135A1 (ja) | 2003-10-24 | 2007-03-08 | 小野薬品工業株式会社 | 抗ストレス薬およびその医薬用途 |
US20050176755A1 (en) | 2003-10-31 | 2005-08-11 | Dyatkin Alexey B. | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
PT1682537E (pt) | 2003-11-05 | 2012-06-20 | Sarcode Bioscience Inc | Moduladores de adesão celular |
WO2005046696A1 (ja) | 2003-11-14 | 2005-05-26 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤 |
JP4947482B2 (ja) | 2003-11-14 | 2012-06-06 | 味の素株式会社 | フェニルアラニン誘導体の徐放性経口投与製剤 |
WO2005051925A1 (ja) | 2003-11-27 | 2005-06-09 | Ajinomoto Co., Inc. | フェニルアラニン誘導体の結晶及びその製造方法 |
GB0329584D0 (en) | 2003-12-20 | 2004-01-28 | Tanabe Seiyaku Co | Novel compounds |
AU2004303696B2 (en) | 2003-12-22 | 2011-03-31 | Ea Pharma Co., Ltd. | Novel phenylalanine derivative |
MY140489A (en) | 2003-12-26 | 2009-12-31 | Eisai R&D Man Co Ltd | 1,2-di (cyclic) substituted benzene compounds |
US7595318B2 (en) | 2004-01-23 | 2009-09-29 | Elan Pharmaceuticals, Inc. | Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids |
KR20070004676A (ko) | 2004-02-10 | 2007-01-09 | 얀센 파마슈티카 엔.브이. | 알파4 인테그린의 길항제로서의 피리다지논 |
ATE371649T1 (de) | 2004-02-10 | 2007-09-15 | Janssen Pharmaceutica Nv | Pyridazinonharnstoffe als antagonisten von a4- integrinen |
CA2558893A1 (en) | 2004-03-10 | 2005-09-22 | Merck & Co., Inc. | Vla-4 antagonists |
AU2005231467A1 (en) | 2004-04-01 | 2005-10-20 | Elan Pharmaceuticals, Inc. | Steroid sparing agents and methods of using same |
AU2005244751A1 (en) | 2004-04-16 | 2005-12-01 | Genentech, Inc. | Method for augmenting B cell depletion |
US7618981B2 (en) | 2004-05-06 | 2009-11-17 | Cytokinetics, Inc. | Imidazopyridinyl-benzamide anti-cancer agents |
TW200610754A (en) | 2004-06-14 | 2006-04-01 | Daiichi Seiyaku Co | Vla-4 inhibitor |
MX2007000228A (es) | 2004-07-08 | 2007-03-30 | Elan Pharm Inc | Antagonistas de vla-4 multivalentes que comprenden porsiones de polietilenglicol. |
US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
CA2576647C (en) | 2004-08-16 | 2011-12-13 | Merck & Co., Inc. | Vla-4 antagonists |
WO2006028393A1 (en) | 2004-09-09 | 2006-03-16 | Auckland Uniservices Limited | Novel peptides and methods for the treatment of inflammatory disease |
US7618983B2 (en) | 2004-11-10 | 2009-11-17 | Janssen Pharmaceutica, N.V. | Bicyclic triazole α4 integrin inhibitors |
US7910734B2 (en) | 2004-12-20 | 2011-03-22 | Eisai R&D Management Co., Ltd. | Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
WO2006066780A1 (en) | 2004-12-22 | 2006-06-29 | F. Hoffmann-La Roche Ag | Combinations of valategrast and montelukast for treating asthma |
DK1840121T3 (da) | 2004-12-24 | 2012-11-26 | Toray Industries | Glycinderivat og anvendelse heraf |
WO2006081986A1 (en) | 2005-02-07 | 2006-08-10 | F.Hoffmann-La Roche Ag | Bambuterol and integrin inhibitor combination |
WO2006090234A1 (en) | 2005-02-22 | 2006-08-31 | Ranbaxy Laboratories Limited | Heterocyclic derivatives as cell adhesion inhibitors |
US20060223846A1 (en) | 2005-03-08 | 2006-10-05 | Dyatkin Alexey B | Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
US20090048308A1 (en) | 2005-04-14 | 2009-02-19 | Stock Nicholas S | VLA-4 Antagonists |
WO2006112738A1 (en) | 2005-04-19 | 2006-10-26 | Auckland Uniservices Limited | Novel peptides and methods for the treatment of inflammatory disorders |
EP1874299A2 (en) | 2005-04-21 | 2008-01-09 | Merck & Co., Inc. | Vla-4 antagonists |
EP1881982B1 (en) | 2005-05-20 | 2013-11-20 | Elan Pharmaceuticals Inc. | Imidazolone phenylalanine derivatives as vla-4 antagonists |
ATE478854T1 (de) | 2005-05-25 | 2010-09-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von ä2-(3,3,5,5- tetramethylcyclohexyl)phenylüpiperazin |
EP1889827B1 (en) | 2005-05-25 | 2010-08-25 | Eisai R&D Management Co., Ltd. | Process for producing [2-(3,3,5,5-tetramethylcyclohexyl)phenyl]piperazine |
KR20080021085A (ko) * | 2005-06-09 | 2008-03-06 | 유씨비 파마, 에스.에이. | 2,6 퀴놀리닐 유도체, 이들을 제조하는 방법 및 이들의약제로서의 용도 |
KR20080024536A (ko) | 2005-06-21 | 2008-03-18 | 아지노모토 가부시키가이샤 | 페닐알라닌 유도체의 결정, 이의 제조방법 및 이의 용도 |
TW200726767A (en) | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
WO2007069635A1 (ja) | 2005-12-13 | 2007-06-21 | Daiichi Sankyo Company, Limited | Vla-4阻害薬 |
ATE462408T1 (de) | 2006-01-18 | 2010-04-15 | Hoffmann La Roche | Pharmazeutische zusammensetzungen, enthaltend valatograst, und verfahren zu deren herstellung |
MX2008010988A (es) | 2006-02-27 | 2008-10-20 | Elan Pharm Inc | Compuestos de pirimidinil sulfonamida que inhiben la adhesion de los leucocitos mediada por vla-4. |
JP2009531304A (ja) | 2006-02-28 | 2009-09-03 | エラン ファーマシューティカルズ,インコーポレイテッド | α−4阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法 |
BRPI0718988A2 (pt) | 2006-11-22 | 2014-02-11 | Ajinomoto Kk | Método para preparar um derivado de fenilalanina, e, composto |
WO2008064830A1 (en) | 2006-11-27 | 2008-06-05 | Ucb Pharma, S.A. | Bicyclic and heterobicyclic derivatives, processes for preparing them and their pharmaceutical uses |
PT2152701E (pt) | 2007-03-12 | 2016-01-27 | Ym Biosciences Australia Pty | Compostos de fenil amino pirimidina e suas utilizações |
WO2008125210A1 (en) | 2007-04-12 | 2008-10-23 | Ucb Pharma, S.A. | Quinoline and naphthalene derivatives, processes for their preparation and their use in treatment of inflammatory diseases |
CN107021895A (zh) | 2007-06-12 | 2017-08-08 | 尔察祯有限公司 | 抗菌剂 |
US8269009B2 (en) | 2007-12-07 | 2012-09-18 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating liquid tumors |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
CA2724413C (en) | 2008-05-15 | 2016-10-18 | Duke University | Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
PL2604693T3 (pl) | 2008-07-21 | 2016-09-30 | Jednołańcuchowe cząsteczki TNFSF | |
KR20100101056A (ko) | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
CA2756804C (en) | 2009-03-16 | 2020-12-22 | The Governing Council Of The University Of Toronto | Cyclic amino acid molecules and methods of preparing the same |
GB0905641D0 (en) | 2009-04-01 | 2009-05-13 | Serodus As | Compounds |
BRPI1015259A2 (pt) | 2009-04-27 | 2016-05-03 | Elan Pharm Inc | antagonistas de piridinona de integrinas alfa-4 |
MX2012004707A (es) | 2009-10-21 | 2012-06-08 | Glaxo Group Ltd | Proceso para la preparacion de un derivado de fenilalanina. |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
EP2554169B1 (en) | 2010-03-29 | 2019-11-20 | EA Pharma Co., Ltd. | Pharmaceutical preparation comprising phenylalanine derivative |
EP2554542B1 (en) | 2010-03-29 | 2015-10-07 | Ajinomoto Co., Inc. | Phenylalanine derivative hydrochloride salt crystal |
US20120135912A1 (en) | 2010-05-10 | 2012-05-31 | Perseid Therapeutics Llc | Polypeptide inhibitors of vla4 |
WO2011150499A1 (en) | 2010-05-31 | 2011-12-08 | The Governing Council Of The University Of Toronto | A method to insert molecular fragments into cyclic molecules |
WO2011159781A2 (en) | 2010-06-17 | 2011-12-22 | Senomyx, Inc. | Bitter taste modulators |
US8680288B2 (en) | 2010-07-20 | 2014-03-25 | Council Of Scientific & Industrial Research | Pyridin-2yl sulfanyl acid esters and process for the preparation thereof |
DK2881393T3 (en) | 2010-11-16 | 2018-07-23 | Texas Heart Inst | Agonists that enhance the binding of integrin-expressing cells to integrin receptors |
EP2670733B1 (en) | 2011-02-01 | 2019-04-10 | The Board of Trustees of the University of Illionis | N-hydroxybenzamide derivatives as hdac inhibitors and therapeutic methods using the same |
CA2854658A1 (en) | 2011-11-09 | 2013-05-16 | Aestus Therapeutics, Inc. | Methods of treating schizophrenia with phenylalanine enamide derivative inhibitors of .alpha.4 integrin possessing a cyclobutene group |
CN104023751B (zh) | 2012-01-27 | 2016-11-09 | 弗·哈夫曼-拉罗切有限公司 | 靶向递送至表达vla-4的细胞的整联蛋白拮抗剂结合物 |
WO2013110681A1 (en) | 2012-01-27 | 2013-08-01 | F. Hoffmann-La Roche Ag | Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
US20130303763A1 (en) | 2012-03-30 | 2013-11-14 | Michael D. Gershon | Methods and compositions for the treatment of necrotizing enterocolitis |
KR101698796B1 (ko) | 2012-04-24 | 2017-01-23 | 이에이 파마 가부시키가이샤 | 설폰아미드 유도체 및 이의 의약 용도 |
US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
US9610264B2 (en) | 2012-09-26 | 2017-04-04 | Kflp Biotech, Llc | Compounds for the treatment and prevention of retroviral infections |
JPWO2014051056A1 (ja) | 2012-09-28 | 2016-08-22 | 東レ株式会社 | グリシン誘導体の結晶及びその医薬用途 |
US20150045435A1 (en) | 2013-08-06 | 2015-02-12 | Indiana University Research And Technology Corporation | Compounds and methods for treating diabetes |
JP6399874B2 (ja) | 2013-09-20 | 2018-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 化合物の抗炎症効果または免疫抑制効果を予測する方法 |
KR101806103B1 (ko) | 2013-10-29 | 2017-12-07 | 이에이 파마 가부시키가이샤 | 설폰아미드 유도체 및 이의 의약 용도 |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
WO2015172196A1 (en) | 2014-05-13 | 2015-11-19 | Monash University | Heterocyclic compounds and use of same |
JP2016037467A (ja) | 2014-08-07 | 2016-03-22 | 味の素株式会社 | スルホンアミド誘導体及びその医薬用途 |
JP2016037468A (ja) | 2014-08-07 | 2016-03-22 | 味の素株式会社 | スルホンアミド誘導体及びその医薬用途 |
SG10201901192TA (en) | 2014-09-10 | 2019-03-28 | Epizyme Inc | Smyd inhibitors |
BR112017006272A2 (pt) | 2014-09-29 | 2018-03-13 | Ea Pharma Co., Ltd. | composição farmacêutica para tratar colite ulcerativa. |
US10383842B2 (en) | 2015-02-13 | 2019-08-20 | Global Biolife Inc. | Method and composition for preventing and treating viral infections |
CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
MA42016A1 (fr) | 2015-07-08 | 2018-03-30 | Axerovision Inc | Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires |
EP4112611A3 (en) | 2015-10-23 | 2023-03-22 | Navitor Pharmaceuticals, Inc. | Modulators of sestrin-gator2 interaction and uses thereof |
CN105483206B (zh) | 2016-01-06 | 2019-09-13 | 北京汉氏联合生物技术股份有限公司 | 一种用vcam-1检测msc促内皮细胞增殖能力的方法 |
JP6809713B2 (ja) | 2016-01-20 | 2021-01-06 | 国立大学法人 岡山大学 | 炎症性腸疾患抑制剤 |
CN106995439B (zh) | 2016-01-26 | 2019-09-20 | 镇江圣安医药有限公司 | 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途 |
WO2017132620A1 (en) | 2016-01-29 | 2017-08-03 | La Jolla Institute For Allergy And Immunology | Methods and compositions using integrin-based therapeutics |
TW201731824A (zh) | 2016-02-05 | 2017-09-16 | Ea Pharma Co Ltd | α4β7整合蛋白抑制劑 |
HUE053354T2 (hu) | 2016-02-05 | 2021-06-28 | Ea Pharma Co Ltd | Szulfonamid-származékok és ezeket tartalmazó gyógyászati készítmények |
EP3509590A4 (en) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING |
MX2019003425A (es) | 2016-09-28 | 2019-08-16 | Blade Therapeutics Inc | Moduladores de calpainas y usos terapeuticos de los mismos. |
WO2018085574A2 (en) | 2016-11-02 | 2018-05-11 | Washington University | Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof |
WO2018085552A1 (en) | 2016-11-02 | 2018-05-11 | Saint Louis University | Integrin antagonists |
BR112019009245A2 (pt) | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
AU2017359023B2 (en) | 2016-11-08 | 2021-12-09 | Bristol-Myers Squibb Company | 3-substituted propionic acids as alpha v integrin inhibitors |
WO2018089360A1 (en) | 2016-11-08 | 2018-05-17 | Bristol-Myers Squibb Company | Pyrrole amides as alpha v integrin inhibitors |
JP7213804B2 (ja) | 2016-11-08 | 2023-01-27 | ブリストル-マイヤーズ スクイブ カンパニー | αVインテグリンアンタゴニストとしてのインダゾール誘導体 |
TW201819378A (zh) | 2016-11-08 | 2018-06-01 | 美商必治妥美雅史谷比公司 | 作為αv整合素抑制劑之含環丁烷及氮雜環丁烷之單及螺環化合物 |
WO2018160522A1 (en) | 2017-02-28 | 2018-09-07 | Lazuli, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
MA47697A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'(alpha-v)(bêta-6) intégrine |
US10875875B2 (en) | 2017-04-26 | 2020-12-29 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
CN116370448A (zh) | 2017-04-26 | 2023-07-04 | 纳维托制药有限公司 | Sestrin-gator2相互作用的调节剂及其用途 |
US10246451B2 (en) | 2017-04-26 | 2019-04-02 | Aviara Pharmaceuticals, Inc. | Propionic acid derivatives and methods of use thereof |
JP2019031449A (ja) | 2017-08-04 | 2019-02-28 | Eaファーマ株式会社 | スルホンアミド誘導体及びそれを含有する医薬組成物 |
CN109721605B (zh) | 2017-10-31 | 2022-03-11 | 维眸生物科技(上海)有限公司 | 一种免疫细胞迁徙抑制剂 |
AU2018365793A1 (en) | 2017-11-07 | 2020-06-18 | Bristol-Myers Squibb Company | Pyrrolopyrazine derivatives as alpha V integrin inhibitors |
KR20200139676A (ko) | 2018-03-07 | 2020-12-14 | 플라이언트 테라퓨틱스, 인크. | 아미노산 화합물 및 사용 방법 |
EP3765005A4 (en) | 2018-03-13 | 2022-02-23 | The Regents of the University of California | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHOD OF USE |
CN112312910A (zh) | 2018-04-12 | 2021-02-02 | 莫菲克医疗股份有限公司 | 人整合素α4β7拮抗剂 |
WO2020033724A1 (en) | 2018-08-08 | 2020-02-13 | The General Hospital Corporation | Integrin antagonists |
EP3613739B1 (en) | 2018-08-17 | 2020-11-04 | Oxurion NV | Integrin antagonists |
SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INTEGRIN (ALPHA-V)(BETA-6) INHIBITORS |
EP3843728A4 (en) | 2018-08-29 | 2022-05-25 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
CA3114240C (en) | 2018-10-30 | 2023-09-05 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
BR112021007213A2 (pt) | 2018-10-30 | 2021-08-10 | Gilead Sciences, Inc. | derivados de quinolina como inibidores de integrina alfa4beta7 |
AU2020329207B2 (en) | 2019-08-14 | 2024-02-29 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
-
2019
- 2019-10-29 CA CA3115820A patent/CA3115820A1/en active Pending
- 2019-10-29 JP JP2021548531A patent/JP7189368B2/ja active Active
- 2019-10-29 EP EP19805082.5A patent/EP3873897A1/en active Pending
- 2019-10-29 WO PCT/US2019/058583 patent/WO2020092383A1/en unknown
- 2019-10-29 KR KR1020217016033A patent/KR102652797B1/ko active IP Right Grant
- 2019-10-29 CN CN201980071791.8A patent/CN112996786A/zh active Pending
- 2019-10-29 US US16/667,373 patent/US11224600B2/en active Active
- 2019-10-29 AU AU2019373242A patent/AU2019373242B2/en active Active
- 2019-10-30 TW TW108139359A patent/TWI800691B/zh active
-
2021
- 2021-12-14 US US17/550,591 patent/US20220226337A1/en not_active Abandoned
-
2022
- 2022-08-04 JP JP2022124856A patent/JP2022140761A/ja not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999036393A1 (en) * | 1998-01-20 | 1999-07-22 | Tanabe Seiyaku Co., Ltd. | INHIBITORS OF α4 MEDIATED CELL ADHESION |
Also Published As
Publication number | Publication date |
---|---|
US20200155563A1 (en) | 2020-05-21 |
WO2020092383A1 (en) | 2020-05-07 |
US20220226337A1 (en) | 2022-07-21 |
AU2019373242A1 (en) | 2021-05-13 |
CN112996786A (zh) | 2021-06-18 |
TW202033493A (zh) | 2020-09-16 |
JP2022509509A (ja) | 2022-01-20 |
US11224600B2 (en) | 2022-01-18 |
AU2019373242B2 (en) | 2023-07-13 |
JP2022140761A (ja) | 2022-09-27 |
EP3873897A1 (en) | 2021-09-08 |
CA3115820A1 (en) | 2020-05-07 |
KR20210086672A (ko) | 2021-07-08 |
KR102652797B1 (ko) | 2024-04-02 |
JP7189368B2 (ja) | 2022-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI800691B (zh) | 抑制α4β7整合素的化合物 | |
EP3827009A4 (en) | HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY | |
EP3787627A4 (en) | SUBSTITUTED HETEROCYCLIC INHIBITORS FOR PTPN11 | |
EP3752491A4 (en) | HETEROCYCLIC COMPOUNDS USED AS KINASE INHIBITORS | |
EP3813805A4 (en) | COMPOUNDS FOR INHIBITION OF INFLAMMATION | |
EP3801503A4 (en) | INHIBITORS OF SARM1 | |
EP3906029A4 (en) | INHIBITORS OF MENIN-MLL INTERACTION | |
EP3712130A4 (en) | METHOD OF SYNTHESIS OF ROXADUSTATE AND INTERMEDIATE COMPOUNDS THEREOF | |
EP3896060A4 (en) | HETEROCYCLIC COMPOUND | |
EP3551625A4 (en) | HETEROCYCLIC MCT4 INHIBITORS | |
EP3873474A4 (en) | HETEROCYCLIC COMPOUNDS AS BET Inhibitors | |
EP3611171A4 (en) | METHOD OF SYNTHESIS OF ELIGLUSTAT AND INTERMEDIATE COMPOUNDS THEREOF | |
EP3895707A4 (en) | HETEROCYCLIC COMPOUND | |
EP3675858A4 (en) | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | |
EP3884053A4 (en) | COMPOUNDS AND METHODS FOR REDUCING PRION EXPRESSION | |
EP3553065A4 (en) | HETEROCYCLIC CONNECTION AS A SYK INHIBITOR AND / OR SYK-HDAC DOUBLE INHIBITOR | |
EP3888652A4 (en) | HETEROCYCLIC COMPOUND | |
EP3752001A4 (en) | SOBETIROMA DERIVATIVES | |
IL288987A (en) | New heterocyclic compounds | |
EP3844162A4 (en) | INHIBITORS OF AV-BETA6 INTEGRIN | |
EP3801499A4 (en) | INHIBITORS OF SARM1 | |
EP3801500A4 (en) | INHIBITORS OF SARM1 | |
EP3747885A4 (en) | HETEROCYCLIC CONNECTION | |
EP3693360A4 (en) | HETEROCYCLIC COMPOUNDS | |
EP3801525A4 (en) | PROLYL-ARNT-SYNTHETASE INHIBITORS |